OneMedNet (ONMD) Stock Price, News & Analysis

OneMedNet Corporation (NASDAQ: ONMD) operates in the professional, scientific, and technical services sector, with a focus on research and development in the physical, engineering, and life sciences fields. According to company disclosures and recent news, OneMedNet describes itself as a curator and provider of regulatory-grade, AI-ready Real-World Data (RWD) through its proprietary iRWD™ platform. The company emphasizes a large, live network of healthcare provider sites and access to de-identified clinical data that can be used by life sciences, medical device, diagnostics, and healthcare AI organizations.

Across multiple press releases, OneMedNet states that its iRWD™ platform aggregates multimodal clinical information, including de-identified medical imaging and electronic health records, to support evidence generation, model development, and regulatory-grade validation in areas such as rare diseases, oncology, and cardiology. The company highlights that its network spans thousands of healthcare sites and tens of millions of de-identified patient records and clinical exams, positioning its data assets as a resource for drugmakers, medical device companies, contract research organizations, and AI developers seeking large-scale, longitudinal datasets.

Business Focus and iRWD™ Platform

Based on the company’s own descriptions in its news releases, OneMedNet’s core business centers on:

• Real-World Data curation: Curating regulatory-grade, de-identified RWD from a broad network of provider sites, with an emphasis on imaging and associated clinical data.
• Multimodal datasets: Providing multimodal data that can include medical imaging, clinical records, and other structured and unstructured clinical information to create comprehensive patient-level views.
• AI-ready infrastructure: Presenting its data as AI-ready, with the company highlighting use cases such as training, validating, and monitoring AI models in healthcare and supporting Real-World Evidence (RWE) programs.
• Subscription and project-based access: Offering recurring subscription access through Live Data Feeds and AI-driven conversational search, as well as project-based data deliveries under master service agreements, as described in its announcements.

The company reports that it has entered into multi-year subscription agreements and evergreen master service agreements with healthcare AI and medical device partners, under which it delivers curated, de-identified datasets tailored to specific research and development needs. OneMedNet emphasizes that its data is intended to meet regulatory expectations for Real-World Evidence and to support activities such as clinical research, post-market surveillance, and market access analysis.

Technology Partnerships and AI Capabilities

In several news releases, OneMedNet describes a strategic relationship with Palantir Technologies. The company states that Palantir’s Artificial Intelligence Platform (AIP) and Foundry environment provide infrastructure for OneMedNet’s near real-time, AI-powered provider network and for its redesigned data exploration and cohort-building platform. According to these disclosures, this integration is intended to enable:

• Faster data discovery and cohort feasibility assessments, moving from days to minutes for complex queries.
• AI-driven de-identification at scale for large data orders.
• Natural-language, conversational search across multimodal clinical datasets.
• Integration with healthcare coding standards, such as SNOMED, HCPCS, ICD-10, and CPT, to support interoperable access for life sciences users.

OneMedNet also notes that its proprietary AI algorithms are used for anonymization and de-identification of clinical data on Palantir’s platform, with the stated goal of maintaining regulatory compliance and protecting protected health information while enabling data use for research and analytics.

Customer Segments and Use Cases

From the company’s own statements, OneMedNet targets several customer groups within the healthcare and AI ecosystems. These include global pharmaceutical companies, medical device manufacturers, diagnostics firms, contract research organizations, and healthcare AI and analytics companies. The company reports that these customers use OneMedNet’s regulatory-grade RWD to:

• Develop and validate AI models for medical imaging and other clinical applications.
• Support Real-World Evidence programs and observational studies.
• Enhance clinical trial design and feasibility through rapid cohort discovery.
• Conduct post-market surveillance and health economics and outcomes research (HEOR), as referenced in the company’s strategic commentary.

OneMedNet has publicly highlighted specific relationships, such as a multi-year subscription with mlHealth360 and an evergreen agreement with a large medical device company, as examples of how its data services are applied to AI model development and imaging-focused innovation. These disclosures underscore the company’s focus on repeat business and long-term arrangements built around its iRWD™ network.

Expansion into Data Annotation and Non-Healthcare Verticals

In addition to RWD curation and delivery, OneMedNet has announced a partnership with Medcase, a network of healthcare professionals focused on medical data annotation. According to the company, this collaboration provides an entry point into the healthcare data annotation market and is intended to create a complementary revenue stream by pairing OneMedNet’s regulatory-grade RWD with Medcase’s clinician-led annotation services.

The company also states that its proprietary AI anonymization technology is applied beyond healthcare, mentioning finance, retail, and telecom as sectors where its de-identification capabilities can be used to test production system upgrades, reduce project risk, and enable secure sharing of sensitive data by removing personal information. OneMedNet views its anonymization and data handling expertise as applicable across multiple data-intensive industries.

Regulatory and Listing Context

OneMedNet’s SEC filings indicate that it is incorporated in Delaware and maintains its principal executive offices in Eden Prairie, Minnesota. The company’s common stock and redeemable warrants are listed on The Nasdaq Capital Market. In 2025, OneMedNet disclosed that it had received Nasdaq notices regarding the minimum bid price requirement and the minimum market value of listed securities requirement. Subsequent Form 8-K filings state that the company regained compliance with both Nasdaq Listing Rule 5550(a)(2) and Nasdaq Listing Rule 5550(b)(2) after meeting the respective thresholds for the required number of consecutive business days.

The company’s definitive proxy statement describes a typical corporate governance structure, including a board of directors, annual meetings of stockholders, and the use of an independent registered public accounting firm. These filings also outline standard matters such as director elections and auditor ratification, reflecting OneMedNet’s status as a publicly traded company subject to U.S. securities regulation.

Corporate Governance and Shareholder Engagement

In its proxy materials, OneMedNet explains that its annual meeting of stockholders is conducted via live audio webcast, with stockholders able to attend online, submit questions, and vote. The company notes that it uses a Notice of Internet Availability of Proxy Materials to provide access to its proxy statement and annual report, and that stockholders of record and beneficial owners can vote through various channels, including internet and mail.

OneMedNet’s filings also describe board-level matters such as director classes, proposals for director elections, and the ratification of its independent auditor. The company emphasizes that stockholders of record as of a specified record date are entitled to vote at the annual meeting, and it provides information on how stockholders can access the list of stockholders entitled to vote.

Position Within the Real-World Data and Healthcare AI Ecosystem

Across its public communications, OneMedNet presents itself as a participant in the Real-World Data and healthcare AI ecosystem, emphasizing regulatory-grade standards, multimodal data, and AI-enabled access methods. The company references external estimates of the potential size of AI-driven healthcare and Real-World Evidence markets, and frames its iRWD™ platform, provider network, and partnerships as a way to address what it describes as a persistent bottleneck in accessing high-quality, timely, de-identified clinical data.

According to its shareholder communications, OneMedNet’s strategic focus includes expanding its provider network, enhancing its AI-driven platform capabilities, and growing subscription-based access models. The company links these efforts to its stated mission of reducing friction between care providers and researchers and enabling faster development of drugs, medical devices, and healthcare AI solutions.